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ABSTRACT
Packaging of the segmented RNA genome of Brome
mosaic virus (BMV) into discrete particles is an es-
sential step in the virus life cycle; however, ques-
tions remain regarding the mechanism of RNA
packaging and the degree to which the viral coat
protein controls the process. In this study, we
used a plant-derived glycosidase, Pokeweed anti-
viral protein, to remove 14 specific bases from
BMV RNA3 to examine the effect of depurination
on virus assembly. Depurination of A771 within
ORF3 and A1006 in the intergenic region inhibited
coat protein binding and prevented RNA3 incorpor-
ation into particles. The disruption of interaction
was not based on sequence identity, as mutation
of these two purines to pyrimidines did not decrease
coat protein-binding affinity. Rather, we suggest
that base removal results in decreased thermo-
dynamic stability of local RNA structures required
for packaging, and that this instability is detected
by coat protein. These results describe a new level
of discrimination by coat protein, whereby it recog-
nizes damage to specific viral RNA elements in
the form of base removal and selects against
incorporating the RNA into particles.
INTRODUCTION
Packaging is an essential step in the life cycle of a virus,
whereby assembly of viral genomes with virally encoded
coat protein (CP) protects the genome from degradation
and serves as the primary means for transfer of the virus
from one host to the next. For Brome mosaic virus
(BMV), a member of the family Bromoviridae, which in-
fects grasses such as barley, the ability to package its viral
genome into particles is also essential for cell-to-cell
movement and hence systemic infection in plants (1).
The genome of BMV is composed of three single-
stranded, positive-sense messenger RNAs and one sub-
genomic RNA (2,3). RNA1 (3.2kb) and RNA2 (2.9kb)
are monocistronic and encode the 1a and 2a replicase
proteins, respectively (4,5). RNA3 (2.1kb) is dicistronic,
and encodes the 50-proximal movement protein, which is
translated directly from RNA3, and the 30-proximal CP,
which is translated from a subgenomic RNA4 (0.9kb),
synthesized from the 30 open reading frame (ORF) of
RNA3 (6). RNA1 and RNA2 are packaged independently
into separate virus particles, whereas RNA3 and the
subgenomic RNA4 are co-packaged into a third virion
(7). Each viral particle is comprised of either RNA1, 2
or 3 and sgRNA4 along with 180 molecules of CP,
which together form an icosahedral virion (8). Although
other viral and cellular components may assist in the for-
mation of particles in vivo, the ability to reconstitute par-
ticles in vitro from only viral RNA and CP indicates that
particle assembly relies heavily on interactions between
these two components.
Particular regions of RNA3 have been shown to be ne-
cessary for packaging. For example, the 30 tRNA-like
structure found at the terminus of each BMV RNA is
hypothesized to facilitate the pentamer formation of CP
dimers, which are the building blocks of the icosahedral
particle (9). Because the tRNA-like structure is common
to all BMV RNAs and can be functionally replaced by a
cellular tRNA, it is not a speciﬁc packaging signal for
individual RNAs; however, the lack of particle formation
in its absence shows the importance of this structure for
packaging (10). The fact that viral RNAs are distinguished
from cellular RNAs during packaging suggests that
sequence- or shape-speciﬁc regions of each BMV RNA
must exist that are recognized by the CP. A stem–loop
region of the movement protein gene of RNA3 has been
identiﬁed as an RNA element required for efﬁcient
packaging, as its deletion substantially diminished
particle formation (11,12).
In the current study, we have determined that the CP is
selective in packaging of viral RNA, as it is able to distin-
guish between damaged and intact RNAs. Damage was
achieved by depurination, caused by the enzyme activity
of Pokeweed antiviral protein (PAP). PAP is a glycosidase
that has been shown to remove speciﬁc purine bases from
RNA3 and to inhibit accumulation of BMV RNAs in
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depurination sites and determined how missing bases
within the intergenic region and at the 30 end of RNA3
inhibited the initiation and elongation steps of replication,
respectively (14). Here, we show that depurination of
particular nucleotides within ORF3 and the intergenic
region of RNA3 prevents incorporation of RNA3 into
particles. Even though CP does not bind to a portion of
RNA3 containing only the intergenic region, we demon-
strate that when present, the intergenic region enhances
CP interaction with RNA3 ORF3. In addition to contri-
buting new information describing how CP recognizes
RNA3, we also illustrate how depurination inhibits for-
mation of particles, thereby extending our knowledge of
the antiviral activity of PAP to the packaging step of the
virus life cycle.
MATERIALS AND METHODS
Isolation and transfection of barley protoplasts
Protoplasts were isolated from 7-day-old barley leaves
by enzymatic digestion as described previously (15).
Protoplasts (3 10
5) were transfected with capped,
in vitro transcripts of BMV RNAs (1.0mg each) and
25mg of a PAP cDNA, under the control of a constitutive
CaMV promoter, using PEG 1500 as described (13), and
incubated at 25 C under constant ﬂuorescent light
(165mmol/m
2/s) for 18h.
Protoplast protein and nucleic acid analyses
Aliquots of protoplasts transfected with BMV RNAs
and PAP cDNA were removed at indicated time points.
Protoplasts were pelleted at 1000g for 20s and cells were
lysed by adding 300ml of extraction buffer (2 TE, 1%
SDS). Total protein was precipitated by adding 1ml of
100% trichloroacetic acid and the amount of protein
was quantiﬁed by Bradford assay. Immunoblotting to
detect PAP and CP expression was performed as described
(16), using PAP and CP polyclonal antibodies at 1:5000.
Samples were probed for b-actin (monoclonal antibody,
1:5000) as a control for protein loading. Total nucleic
acids were isolated from lysed protoplasts by the addition
of 300ml phenol:chloroform:isoamyl alcohol (PCI). The
aqueous layer was re-extracted and nucleic acids were
precipitated with 100mlo f8 MN H 4OAc and 1ml of
95% ethanol and resuspended in ddH2O. Equal amounts
of total nucleic acids were separated in a 7M urea/4.5%
acrylamide gel and transferred to nylon membrane. To
detect BMV RNAs, the membrane was probed with a
200-nt radiolabeled RNA transcribed from pB3HE1 that
was complementary to the 30 end of all BMV RNAs (13).
As a loading control for total cellular RNA, samples from
cell lysates were probed with an 80-nt radiolabeled RNA
transcript complementary to the 30 end of 25S rRNA (13).
For primer extension analysis, RNA3 was gel puriﬁed
from total RNA isolated from both PAP-expressing and
wild-type cells and depurination sites were identiﬁed as
described previously (14). To estimate the amount of
depurinated wild-type and mutant RNA3 in cells express-
ing PAP, 200ng of the gel-puriﬁed RNA3 was used as
template for reverse transcription. Brieﬂy, a reverse
primer that annealed to the last nucleotide of RNA3
was extended using reverse transcriptase in the presence
of [a
33P]-dATP. cDNA products were separated in a 7M
urea/4.5% acrylamide gel and visualized with a phosphor-
imager. Depurination of particular nucleotides was
evident by truncation of the cDNA products at the
expected sizes relative to full-length RNA3. The intensities
of truncated bands relative to total RNA3 (truncated+
full length) were quantiﬁed to estimate the percent of
depurinated RNA3 in protoplasts.
Virion particle isolation from barley protoplasts
Following transfection and incubation for 18h, proto-
plasts were ground in extraction buffer (0.5M
NaH2PO4, pH 4.5, 80mM MgCl2,1 %b-mercapto-
ethanol). The lysate was then transferred to microcentri-
fuge tubes and centrifuged at 5000g for 15min at 4 C. The
aqueous layer was centrifuged at 171500g for 90min at
4 C through a 10% sucrose cushion. The pellet, contain-
ing virion particles, was resuspended and treated with
1mg/ml of RNase A for 30min at 30 C, to remove unen-
capsidated RNAs. Virions were concentrated in a
100-kDa cut-off centrifugal ﬁlter and resuspended in
virus buffer (50mM NaH2PO4, pH 4.5, 8mM MgCl2).
Infectivity of viral particles
Chenopodium quinoa plants were grown to the four-leaf
stage before inoculation with BMV virion isolated from
barley protoplasts. Isolated virions (15mg) from either
PAP-expressing or wild-type protoplasts were added to
500ml inoculation buffer (10mM NaH2PO4,1 0 m M
MgCl2, 2% silicon carbide). An aliquot of this mixture
(20ml) was rubbed onto a second tier leaf of each plant,
and plants were maintained at 25 C/20 C day/night tem-
perature and 16-h day length with 180-mmol/m
2/s light
intensity. Plants were monitored for the appearance of
local lesions. Nine days post infection, lesions were
counted and leaves were photographed.
Barley infection and virion preparation
Barley plants were grown to the six-leaf stage before in-
oculation with BMV virion. Isolated virions (15mg) were
added to 500ml inoculation buffer (10mM NaH2PO4,
10mM MgCl2, 2% silicon carbide). An aliquot of this
mixture (20ml) was rubbed onto the second tier leaf of
the plant and plants were grown for 15 days post infection.
Plants were maintained under mixed ﬂuorescent and in-
candescent lighting (230mmol/m
2/s) with 14-h days at
20 C and 10-h nights at 18 C. Following incubation, the
systemically infected leaves were ground in 3-ml extraction
buffer (0.5M NaH2PO4, pH 4.5, 80mM MgCl2,1 %
b-mercaptoethanol). The solution was collected by strain-
ing through Miracloth and stirred with equal volume of
chloroform for 30min at 4 C. The solution was then
transferred to microcentrifuge tubes and centrifuged at
5000g for 15min at 4 C. The aqueous layer was then
centrifuged at 171500g for 90min at 4 C through a
10% sucrose cushion. The pellet was resuspended in
virus buffer (50mM NaH2PO4, pH 4.5, 8mM MgCl2).
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source of CP for in vitro assembly of particles, described
below.
CP preparation, virion assembly assays and
electron microscopy
CP was disassembled from isolated BMV particles for
in vitro virion assembly assays as described previously
(17). Virion assembly reactions were conducted as previ-
ously described with minor modiﬁcations (18). For each
virion assembly reaction, puriﬁed BMV CP and wild-type
or mutant RNA3 were mixed in a 1:5 (wt/wt) ratio and
dialyzed for 24h at 4 C in assembly buffer (100ml; 50mM
NaCl, 50mM Tris–HCl, pH 7.2, 10mM KCl, 5mM
MgCl2, 1mM DTT). Following dialysis, assembled par-
ticles were isolated by centrifugation at 171500g for
90min at 4 C through a 10% sucrose cushion. The
pellet, containing virion particles, was resuspended and
treated with 1mg/ml of RNase A for 30min at 30 Ct o
remove unencapsidated RNA. Assembled virions were
concentrated in a 100-kDa cutoff centrifugal ﬁlter and
resuspended in virus buffer (50mM NaH2PO4, pH 4.5,
8mM MgCl2). In some cases, the RNA3 was treated
with PAP prior to assembly, as described previously
(14). Assembled particles were negatively stained with
1% uranyl acetate and visualized with a transmission
electron microscope (Philips EM210). Percentage value in-
dicates the mean number of particles from PAP-treated
RNA3 relative to untreated RNA3±SE from ﬁve ﬁelds
of view.
Virion RNA analysis
RNA was isolated from virions as described previously
(19) and equal volume of RNA was separated in a 7M
urea/4.5% acrylamide gel for northern blot analysis as
described above. For primer extension analysis, RNA3
was isolated from gel slices of either total protoplast
RNA or total virion RNA separated through 7M urea/
4.5% acrylamide. The extension reaction was performed
as described previously (14). For real-time quantitative re-
verse transcriptase-polymerase chain reaction (RT–PCR
and radiolabeled PCR, equal amounts of isolated RNA3
from virions (0.5mg), along with a positive control depur-
inated RNA3 (0.5mg) were reverse-transcribed with
SuperScript-II-RT. Quantitative PCR was performed
with 200nM of both sense and antisense primers (50 GT
AAAATACCAACTAATTCTCG 30;5 0 TGGTCTC TTT
TAGAGATTTACAGTG 30) in a ﬁnal volume of 25ml
using the SYBR Green PCR core reagent (Invitrogen) in
an ABI PRISM 7700 Sequence Detection System
Instrument (Applied Biosystems). Known amounts of
DNA3 were also ampliﬁed to generate a standard curve
and the equation Y=29.56 X
 0.0335. Quantitation of the
PCR products was determined using the cycle threshold
(Ct) values obtained. Radiolabeled PCR was conducted in
the presence of [a
33P]-dATP (10mCi/ml; GE Healthcare)
using a forward primer that annealed to the ﬁrst nucleo-
tide of BMV and reverse primer that annealed to the last
nucleotide of BMV RNA3, resulting in ampliﬁcation of a
2113-bp fragment.
Construction of PAP-resistant cDNA3 mutants and
A1006 deletion mutant
To create PAP-resistant cDNA3, a series of overlapping
PCRs was conducted to mutate all the observed
depurinated nucleotides in BMV RNA3 from purines to
pyrimidines. The mutations, written as nucleotide change
and (amino acid change), were as follows: A116T (S to C),
A285C (D to A), A342T (D to V), A371C (M to L),
A374T (N to Y), A771T (D to V), G901C (E to A),
A1006C (V to V), A1008C (N to T), A1219T (R to S),
G1225T (M to I), G1544T (V to F), A1953C (D to A),
A1971C(K to T). The resulting resistant cDNA3 was
cloned into the BamHI and EcoRI sites of pBluescript
vector and capped, in vitro transcripts were synthesized.
To produce the cDNA3 mutant for which only A771
could be potentially depurinated (R-RNA3 771), the re-
sistant cDNA3 was used as template for overlapping PCR
to re-introduce the wild-type A771 in place of the pyrimi-
dine T771 from R-cDNA3. Using the same strategy, the
resistant cDNA3 was used as template for overlapping
PCR to re-introduce the wild-type A1006 in place of the
pyrimidine C1006 from R-cDNA3 to create R-RNA3
1006, and the two nucleotides together were reverted to
wild-type to create the mutant R-RNA3 771 1006, which
could be depurinated only at A771 and A1006. To
produce the cDNA3 mutant that was resistant to
depurination only at A771 (RNA3 771-R) or A1006
(RNA31006-R), wild-type cDNA3 was used as template
for overlapping PCR to exchange A771 for T771 or A1006
for C1006, respectively. In the same manner, the double
mutant resistant to depurination at A771 and A1006
(RNA3 771 1006-R) was created by overlapping PCR to
exchange A771 for T771 and A1006 for C1006, using
wild-type cDNA3 as template. The deletion mutant
missing A1006 (RNA3 1006) was constructed by
overlapping PCR using wild-type cDNA3 as template.
These mutant constructs were cloned into the BamHI
and EcoRI sites of pBluescript vector and capped,
in vitro transcripts were synthesized.
Construction of RNA3 fragments, electrophoretic mobility
shift assay and ﬁlter binding
The mutant cDNA3 with all observed depurinated nucleo-
tides changed from purines to pyrimidines, except A771
and A1006 (R-RNA3 771 1006), was used as the template
DNA for a series of PCRs to create less than full-length
RNA3. A forward primer that annealed at nucleotide 92
and reverse primer that annealed at nucleotide 1246 were
used to create a DNA3 fragment encoding RNA3 ORF3
and the intergenic region (ORF3+IGR). A forward
primer annealed at nucleotide 92 and reverse primer at
nucleotide 1003 were used to produce a DNA3 fragment
encoding RNA3 ORF3 only (ORF3 771). A forward
primer 1004 and reverse primer 1246 were used to create
a DNA3 construct encoding RNA3 intergenic region
(IGR). These fragments were cloned into the BamHI
and EcoRI sites of pBluescript vector and used as
template to transcribe radiolabeled
33P-labeled RNA3
fragments. These in vitro transcripts were treated with
PAP or buffer only (14) and used to perform
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binding analysis with isolated BMV CP. Increasing
amounts of CP were incubated with PAP-treated or un-
treated
33P-labeled RNA3 fragments in binding buffer
[50mM Tris–HCl, pH 7.5, 50mM NaCl, 4mM MgCl2,
1mM DTT, 1mM ethylenediaminetetraacetic acid
(EDTA), 5% glycerol] at room temperature for 30min.
For EMSA, the samples were separated through 6%
non-denaturing acrylamide gels, and radiolabel was vis-
ualized with a phosphorimager. For ﬁlter-binding analysis,
the samples were passed through a nitrocellulose ﬁlter.
The amount of retained, labeled RNA was determined
by scintillation counting and corrected by subtracting
background counts in the absence of BMV CP. The Kd
values were extrapolated after the results were ﬁtted with
the one site binding equation using Graphpad Prism 4.0.
Construction of RNA3 fragment and UV melting analysis
A 162-nt fragment of RNA3 containing A771 was created
by PCR using a forward primer that annealed at nucleo-
tide 679 and reverse primer that annealed at nucleotide
840 on wild-type cDNA3. The only nucleotide that
could be depurinated by PAP within the resulting RNA
fragment was A771. A PAP-resistant form of this RNA3
fragment was created by PCR using the same primers but
R-cDNA3 as template, in which all observed depurinated
purines were exchanged for pyrimidines. The resulting
cDNA3 fragment contained the mutation A771T, which
could not be depurinated in the RNA transcript. The
wild-type and mutant cDNA3 fragments were cloned
into the BamHI and EcoRI sites of pBluescript vector
and capped, in vitro transcripts were synthesized. The
in vitro transcripts were PAP-treated or incubated in
buffer alone, as described previously (14). Primer exten-
sion conﬁrmed that the fragment was as susceptible to
depurination at A771 as full-length RNA3 (data not
shown). Transcripts were resuspended in buffer (10mM
Tris–HCl, pH 7.0, 5mM NaCl) and were heated to 85 C
and then cooled on ice prior to melting temperature
analysis. The absorbance of the samples was monitored
at 260nm from 25 to 85 C. Data were collected with a rate
of change in temperature of 1 C/min using a
Beckman-Coulter DU 800 UV/VIS spectrophotometer
with a Peltier Temperature Programmer. The ﬁrst tem-
perature derivatives of the absorbance at 260nM (dA260/
dT) were plotted against increasing temperature. The
maximum point of each plot represents the melting tem-
perature (Tm) of each fragment.
RESULTS
PAP decreases the production of virus from protoplasts
To investigate the effect of PAP on virus packaging, we
transfected BMV RNA1, 2 and 3 into barley protoplasts
expressing PAP and isolated virus particles from the cells.
Transmission electron microscopy indicated no visible dif-
ference in morphology of particles isolated from
PAP-expressing compared with wild-type protoplasts
(Figure 1A). However, fewer particles were isolated from
cells expressing PAP (21% relative to  PAP), which was
also evident when the same volume of isolated virus was
probed by northern blot and less viral RNAs were seen
associated with particles from PAP-expressing cells (25%
relative to  PAP, compare+PAP with RNase A to  PAP
with RNase A; Figure 1B). To ensure that RNA not
within particles was excluded from the virion preparation,
resuspended particles following centrifugation were
treated with RNase A prior to northern blot analysis.
The intensities of bands in Figure 1B showed no signiﬁ-
cant difference between nuclease-treated and -untreated
particles, indicating a lack of free unencapsidated RNAs.
As a control for RNase A activity, BMV RNAs isolated
from virions were also treated with the nuclease and show
complete degradation (absence) of the RNA.
To assess whether this decrease in particle number
correlated with less total BMV RNA in PAP-expressing
protoplasts, total RNA and virion RNA were isolated
from PAP-expressing protoplasts and their levels com-
pared with wild-type cells (Figure 1C). The amount of
total BMV RNA in PAP-expressing cells 18h after trans-
fection was consistently less than cells not expressing PAP,
which agrees with our previous results showing that PAP
inhibits the replication, and hence accumulation, of BMV
RNAs (13). However, the ratio of signal intensities be-
tween virion RNA and total BMV RNA indicates that
less RNA was packaged relative to the total amount in
cells expressing PAP (0.36) compared with wild-type cells
(0.61). This difference in ratio suggests that the lack of
virion production was not solely due to less viral RNA
in PAP-expressing cells, but that a portion of the total
BMV RNA was excluded from particles. To conﬁrm the
expression of PAP and CP in barley protoplasts, we tested
aliquots of cells over time, from co-transfection of the
PAP encoding plasmid with the three infectious tran-
scripts of BMV RNA (0h) to time of harvest (18h). The
overlap in expression pattern of PAP and CP indicates
that the protein components required to test the effect
of PAP on packaging were present in protoplasts
(Figure 1D). Taken together, these data suggest that the
lack of virion production in PAP-expressing cells was not
due to insufﬁcient total BMV RNA or CP synthesis in
protoplasts.
PAP does not alter the quality of virus from protoplasts
To examine the quality of the viral RNA packaged, quan-
titative PCR was performed using RNA3 from virions as
template. The premise of this test is that if the viral RNA
were depurinated by PAP, the presence of a missing base
would stall the RT and less than full-length cDNA would
be produced which would not be ampliﬁed in the real-time
PCR reaction. A positive control was generated for this
assay by using RNA3 incubated with PAP in vitro as
template for the RT (Figure 2A, control). The same
amount of RNA3 isolated from virions of PAP-expressing
and wild-type protoplasts resulted in similar amounts of
PCR product, indicating that the quality of the RNA3
within viral particles was not signiﬁcantly different. The
relative quantity was substantially greater than that of
RNA3 treated in vitro with PAP (control), suggesting
that depurinated RNA3 was not present in virions of
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followed by radiolabeled PCR indicated the same trends;
that is, the intensity of PCR products from RNA3 tem-
plates isolated from virions of PAP-expressing and wild-
type protoplasts was similar and substantially greater than
the depurinated control template (Figure 2B). Therefore,
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Figure 1. PAP decreases the production of virus from protoplasts.
Barley protoplasts were transfected with a plasmid encoding the PAP
gene (+PAP) or empty plasmid ( PAP), plus BMV RNA1, 2 and 3
in vitro transcripts and incubated for 18h. (A) Electron micrographs of
virions isolated from PAP-expressing (right) and wild-type protoplasts
(left). Viral particles were visualized by staining with uranyl acetate and
viewing at 100000 . The scale bar represents 50nm. Percentage value
indicates the mean number of particles from PAP-expressing cells
relative to wild-type cells±SE from ﬁve ﬁelds of view. (B) Viral
RNAs were puriﬁed from equal volume (20ml) of the isolated viral
particles and analyzed by northern blot for the presence of
positive-strand BMV RNAs. To ensure that no unincorporated BMV
RNAs were included, a portion of the pelleted virion fraction was re-
suspended and treated with RNase A or left untreated. Control
Figure 1. Continued
indicates BMV RNAs isolated from virions treated or untreated with
RNase A. Values are means of intensities for BMV RNAs±SE for
three separate experiments. (C) Northern blot analysis indicating the
levels of total BMV RNAs from protoplast cell lysates and from virus
particles isolated from PAP-expressing or wild-type cells, 18h after
transfection. Total RNA from cell lysates was also probed for 28S
rRNA as a loading control. Values are means of intensities for BMV
RNAs±SE for three separate experiments. (D) Immunoblot analysis
of total cell lysate from protoplasts transfected with a PAP cDNA and
in vitro transcripts of BMV RNA1, 2 and 3 over time. Zerohours
represent the time at transfection and 18h represent the time of cell
harvest. Equal amounts of total protein (10mg) were separated by 12%
SDS–PAGE, transferred to nitrocellulose and probed with an antibody
to PAP (1:5000), BMV CP (1:5000) or b-actin (1:5000).
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Figure 2. PAP does not alter the quality of virus from protoplasts.
Barley protoplasts were transfected with a plasmid encoding the PAP
gene (+PAP) or empty plasmid ( PAP), plus BMV RNA1, 2 and 3
in vitro transcripts and incubated for 18h. Virion particles were isolated
from cells and BMV RNAs associated with particles were separated
through 7M urea/4.5% acrylamide gel. Gel puriﬁed RNA3 (0.5mg)
was reverse transcribed (RT) and used for quantitative PCR (A) and
radioactive PCR (B). Quantitative PCR results are plotted as micro-
gram amount of DNA product. The control lane represents in vitro
PAP-treated RNA3 used for RT–PCR. Values of radioactive PCR
are means of intensities for RNA3±SE for three separate experiments.
(C) Virion particles were isolated from PAP-expressing and wild-type
protoplasts and equal amounts (15mg) were used to infect Chenopodium
quinoa plants. Infectivity of viral particles was assessed by counting the
number of lesions, 9 days post infection. Percentage value indicates the
mean number of lesions on leaves of plants infected with particles taken
from PAP-expressing barley protoplasts (+PAP), relative to particles
isolated from wild-type protoplasts (–PAP)±SE from ﬁve leaves.
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ments to examine the quality of the packaged RNA3.
Equal amounts of virions from PAP-expressing and
wild-type protoplasts were used to infect C. quinoa
plants, a local lesion host of BMV, to determine whether
the two virus preparations were equally infectious. Nine
days following infection, the number of lesions was
counted and no signiﬁcant difference existed between par-
ticles isolated from PAP-expressing protoplasts compared
with wild-type protoplasts (104%±7; Figure 2C). Taken
together, these data suggest that PAP expression in barley
protoplasts does not alter the quality of viral particles
synthesized but reduces the number of particles formed.
PAP depurinates BMV RNA3 in vivo
To investigate how PAP expression may be limiting
particle formation, we ﬁrst tested for the presence of
depurinated viral RNA in cells. Total RNA from wild-
type and PAP-expressing protoplasts transfected with
BMV RNA1, 2 and 3 was isolated and RNA3 analyzed
by primer extension. Ten primers speciﬁc to RNA3 were
extended and 14 depurinated nucleotides were identiﬁed
along its length. Their relative location and nucleotide
numbers are outlined in Figure 3A with examples of
speciﬁc sites (Figure 3B). These same depurinated nucleo-
tides were identiﬁed previously by in vitro incubation
of RNA3 with PAP (14). Therefore, the depurination
pattern of RNA3 seen in vivo from PAP-expressing cells
was the same as we observed previously for in vitro treated
RNA3.
Depurination inhibits packaging of RNA3 in vitro
To investigate whether depurination of BMV RNA
directly affected packaging, virus particles were assembled
using in vitro transcript of PAP-treated or untreated BMV
RNA3 and CP isolated from virions. Assembled viral par-
ticles were examined by transmission electron microscopy
and fewer particles were observed from samples con-
taining PAP-treated RNA3 (29% relative to  PAP;
Figure 4A). No difference in signal intensity of radio-
labeled PCR product was detected for RNA3 from
virions formed from PAP-treated or untreated RNA3,
indicating that the quality of the RNA3 from assembled
particles was the same (Figure 4B). The signal intensity of
PCR product from PAP-treated RNA3 (control) was sub-
stantially less, as would be expected from depurinated
RNA as template. The integrity of RNA3, both before
its assembly and 24h following particle formation, was
veriﬁed by northern blot analysis and no visible degrad-
ation was observed (Figure 4C). These data suggest that
depurination by PAP inhibits viral RNA packaging and
that CP preferentially selects non-depurinated RNA3.
Depurination inhibits binding of CP to RNA3
To test whether CP distinguishes depurinated from intact
RNA3, PAP-treated or untreated RNA3 was incubated
with isolated CP and interaction was assessed by ﬁlter
binding. The afﬁnity of CP for PAP-treated RNA3 was
 6-fold less compared with untreated RNA3 (Kd of
2.32mM versus 0.36mM; Figure 5A). To verify that inhib-
ition of binding was due to depurination, RNA3 was
modiﬁed such that all purines susceptible to removal by
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7214 Nucleic Acids Research, 2011,Vol.39, No. 16PAP were substituted with pyrimidines, thereby making
an RNA3 that could not be depurinated by PAP
(R-RNA3). No signiﬁcant difference in binding afﬁnity
of CP was observed for PAP-treated compared with un-
treated resistant RNA3, indicating that depurination in-
hibited interaction of CP with RNA3 (Figure 5B). In
addition, the dissociation constants for untreated wild-
type compared with untreated resistant RNA3 were the
same, showing that modiﬁcation of these bases from
purines to pyrimidines did not decrease CP binding. The
radiolabeled RNAs were subjected to denaturing gel elec-
trophoresis and visualized by phosphorimager before in-
cubation with CP, to ensure that differences in binding
afﬁnity were not due to degradation of BMV RNA3
upon PAP treatment (Figure 5C).
Depurination within ORF3 reduces packaging efﬁciency
Previous work has shown that an  200-nt region within
BMV ORF3, nucleotides 50 601-817 30, is important for
RNA3 packaging (12; boxed in Figure 6A with structural
model of stem–loop C included). This region may fold into
a structure containing three loops, called stem–loop A, B
and C (12). Deletion of stem–loop B and C completely
abolished assembly in vitro. PAP depurinates A771 (14)
and because this nucleotide is present within stem–loop C,
we hypothesized that depurination of A771 might prevent
RNA3 packaging into virions. To test this idea, the resist-
ant RNA3 (R-RNA3) was modiﬁed to permit depurina-
tion at A771 only (R-RNA3 771), and wild-type RNA3
was modiﬁed such that A771 was mutated to a pyrimidine,
thereby preventing depurination at this nucleotide
but still permitting depurination elsewhere in the RNA3
(RNA3 771-R). These four templates, wild-type RNA3,
PAP-resistant RNA3 (R-RNA3), PAP-resistant RNA3
except for A771 (R-RNA3 771) and RNA3 resistant only
at A771 (RNA3 771-R), were used to assemble particles
in vitro. Line drawings of these RNAs are illustrated in
Figure 6A. Based on northern blot analysis of RNA3
isolated from an equal volume of virus particles, fewer
particles were formed from PAP-treated wild-type
RNA3, whereas no difference was observed for
R-RNA3, as expected (Figure 6B). Fewer particles were
also assembled from RNA3 that was depurinated only at
A771 (R-RNA3 771), indicating that this nucleotide is
important for packaging. Surprisingly, fewer particles
were seen when RNA3 resistant only at A771 (RNA3
771-R) was used for assembly, suggesting that sequences
other than A771 also inﬂuence packaging.
To identify which nucleotides inhibited packaging when
depurinated, apart from A771, primer extension analysis
was conducted on PAP-treated RNA3 resistant only at
A771 (RNA3 771-R) isolated from assembled particles.
All depurinated nucleotides should be detected in par-
ticles, except those required for packaging. The nucleo-
tides shown previously to be depurinated by PAP
treatment were also depurinated in RNA3 from assembled
particles, except A1006 of the intergenic region of RNA3,
and A771, even though the source RNA3 was depurinated
at A1006 following PAP treatment (right panel control;
Figure 6C). The lack of depurination at A771 was
expected, given the substitution of this nucleotide to a
pyrimidine. However, lack of depurination at A1006
suggests that the intergenic region may be important for
packaging, because RNA3 depurinated at this nucleotide
was excluded from particles.
Depurination within the intergenic region reduces
packaging efﬁciency
To investigate the possibility that the intergenic region is
involved in packaging, RNA3 that permitted depurination
only at A1006 (R-RNA3 1006) was incubated with PAP or
untreated and used as template for in vitro particle
assembly. Less RNA3 from PAP-treated template was
isolated from the same volume of particles, suggesting
that depurination only within the intergenic region in-
hibited packaging of RNA3 (Figure 7A, lanes 3 and 4).
Therefore, both ORF3 A771 (Figure 7A, lanes 1 and 2)
and intergenic region A1006 are independently critical for
packaging of BMV RNA3 into virions. We hypothesized
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100000 . The scale bar represents 50nm. Percentage value indicates
the mean number of particles from PAP-treated RNA3 samples relative
to untreated samples±SE from ﬁve ﬁelds of view. (B) Viral RNAs
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Nucleic Acids Research, 2011,Vol.39, No. 16 7215that if both these nucleotides are required, then an RNA3
that cannot be depurinated at both A771 and A1006, but
retains its ability to be depurinated elsewhere, should
allow all of the RNA3 to be packaged, even the depuri-
nated strands. This mutant was synthesized (RNA3 771
1006-R), incubated with PAP and used as template for
virion assembly. The amount of RNA3 isolated from
virions assembled from PAP-treated compared with un-
treated RNA3 was similar (Figure 7A, lanes 5 and 6).
Therefore, depurination of nucleotides apart from A771
and A1006 did not prevent packaging, i.e. depurinated
RNA3 was packaged into particles provided that bases
of A771 and A1006 were not removed. Depurination of
only A771 and A1006 resulted in less RNA3 assembled, as
expected (Figure 7A, lanes 7 and 8) and was similar to
PAP-treated or untreated wild-type RNA3 (Figure 7A,
lanes 9 and 10), indicating that RNA3 depurinated at
A771 and A1006 was excluded from particles.
To test if depurinated RNA3 was present within virion
particles assembled from the mutant that did not permit
depurination of A771 and A1006 (RNA3 771 1006-R),
reverse transcription followed by radioactive PCR was
conducted on equal amounts of RNA3 isolated from par-
ticles. Substantially less PCR product was visualized from
PAP-treated RNA3 compared with untreated RNA3,
indicating that damaged RNA3 was packaged into
virions assembled from the transcript that could not be
depurinated at nucleotides A771 and A1006, but could
be depurinated elsewhere (Figure 7B, lanes 5 and 6). As
expected, an equal amount of PCR product was observed
from RNA isolated from virions made from wild-type
RNA3 or RNA3 susceptible to depurination at A771 or
A1006 (R-RNA3 771, R-RNA3 1006 or R-RNA3 771
1006) treated with PAP, as RNA3 depurinated at either
nucleotide would not be packaged into particles. These
data conﬁrm that nucleotides A771 and A1006 are
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Nucleic Acids Research, 2011,Vol.39, No. 16 7217essential for RNA3 packaging and damage to either or
both inhibits virion assembly.
We were interested to determine whether deletion of one
of these important nucleotides altered the efﬁciency of
RNA3 packaging. We deleted A1006 from the cDNA of
RNA3 and the resulting mutant transcript was used for
in vitro particle assembly. Northern blot analysis of RNA
isolated from the same volume of particles indicated that
RNA3 1006 packaged as well as wild-type RNA3
(Figure 7C). Moreover, PAP treatment of the mutant
prior to assembly reduced the total amount of RNA3
packaged, indicating that depurination of A771 still pre-
vented packaging (conﬁrmed by primer extension, data
not shown). Therefore, the effect on packaging of
deleting one of these nucleotides did not mimic
depurination of the same nucleotide.
CP interaction with RNA3 depurinated at A771 and
A1006
Filter-binding analysis was used to test whether the exclu-
sion from particles of RNA3 depurinated at A771 or
A1006 was due to decrease in CP afﬁnity for these RNA
molecules. CP bound signiﬁcantly less to RNA3
depurinated only at A771 (R-RNA3 771) compared with
non-depurinated RNA3 (Kd of 2.50mM versus 0.23mM;
Table 1). PAP treatment of RNA3 resistant to
depurination except at A1006 (R-RNA3 1006) also signiﬁ-
cantly reduced the afﬁnity of CP; the dissociation constant
for untreated RNA3 was 0.30mM compared to 2.63mM
for PAP-treated RNA3. Finally, CP bound to RNA3
depurinated only at A771 and A1006 (R-RNA3 771
1006) with similar afﬁnity as depurinated wild-type
RNA3 (Kd of 2.89mM versus 2.32mM; Table 1 and
Figure 5A). Therefore, A771 and A1006 are important
for efﬁcient CP binding to RNA3.
BMV CP binds to the 30-UTR of all BMV RNAs
(17,20). To determine whether CP could bind to RNA3
containing only ORF3 and the intergenic region, and if
depurination at nucleotides A771 and A1006 affected
binding, RNA3 fragments were constructed from nucleo-
tides 92–1246 (ORF3+IGR), containing both A771 and
A1006; RNA3 from nucleotides 92–1003 (ORF3), con-
taining A771; and RNA3 from nucleotides 1004–1246
(IGR), containing A1006 (Figure 8A). These three con-
structs were designed to be resistant to depurination
except for A771 and A1006 and the afﬁnity of CP for
these transcripts was analyzed by ﬁlter binding. CP
bound less to the ORF3+IGR fragment relative to
full-length RNA3; the Kd for ORF3+IGR was 0.94mM
compared with Kd of 0.36mM for full-length RNA3
(Figure 8A and 5A), which is consistent with the results
of Yi et al., (17) indicating the importance of the 30 end in
binding. Our results do not preclude the possibility that
CP binds to ORF4, we did not test this. However,
depurination at A771 and A1006 substantially reduced
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Figure 7. Effect of depurination and deletion of A1006 on packaging
efﬁciency. RNA3 constructs, R-RNA3 771, R-RNA3 1006, RNA3 771
1006-R and R-RNA3 7711006 were created by site directed mutagen-
esis. Transcripts of these four RNA3 mutants and wild-type RNA3
were treated with PAP or buffer only. PAP-treated and untreated
RNA3 were used to assemble particles in vitro with isolated CP. (A)
RNA was isolated from equal volume of in vitro assembled particles
and analyzed by northern blot for the presence of positive-strand BMV
RNA3. Values are means of intensities for RNA3±SE for three
separate experiments. (B) Equal amounts of gel puriﬁed RNA3
(0.5mg) from in vitro assembled particles were used for reverse tran-
scription and radioactive PCR. Values are means of intensities for
RNA3±SE for three separate experiments. (C) The deletion construct
RNA3 1006, missing A1006 from RNA3, was created by site-directed
mutagenesis and its in vitro transcript was treated with PAP or buffer
alone. PAP-treated and untreated RNA3 were used to assemble par-
ticles in vitro with isolated CP. RNA was isolated from equal volume of
assembled particles and analyzed by northern blot for the presence of
positive-strand BMV RNA3. Values are means of intensities for
RNA3±SE for three separate experiments.
Table 1. Coat protein afﬁnity for RNA3 depurinated at speciﬁc nu-
cleotides, as measured by ﬁlter-binding assay
RNA3 Mutant KdmM
+PAP  PAP
R-RNA3 771 2.50 0.23
R-RNA3 1006 2.63 0.30
R-RNA3 771 1006 2.89 0.20
7218 Nucleic Acids Research, 2011,Vol.39, No. 16CP binding to ORF3+IGR (Kd of 7.48mM), suggesting
that this fragment does contain a binding site. CP binding
to the ORF3 fragment, in the absence of PAP treatment,
was substantially less than ORF3+IGR, indicating that
the intergenic region contributed to binding of CP to
ORF3 (Kd of 3.07mM for ORF3 compared to 0.94mM
for ORF3+IGR). PAP treatment of ORF3 inhibited
binding, indicating that this region has a CP binding site
that is disrupted by depurination at A771. The CP bound
with low afﬁnity to the intergenic region, suggesting that
this fragment does not contain a CP-binding site.
Moreover, PAP treatment did not alter binding (7.18mM
compared with 6.29mM); therefore, depurination at
A1006 does not affect CP binding to the intergenic
region alone. Taken together, these data show that frag-
ments of RNA3 in addition to the 30 end are important for
CP binding. Moreover, the intergenic region contributes
to the binding of CP to ORF3, even though CP does not
appear to bind to the intergenic region alone.
To further illustrate that ORF3 has a CP-binding site
and that the intergenic region does not, EMSA was con-
ducted with isolated CP and the same fragments,
ORF3+IGR, ORF3 and IGR from R-RNA3 771 1006.
CP caused a shift in ORF3+IGR and a partial shift for
ORF3 and no shift for IGR, indicating that the binding of
CP to movement protein ORF is enhanced by the presence
of IGR, even though CP does not bind to IGR alone
(Figure 8B). No shift was observed following PAP treat-
ment of ORF3+IGR and ORF3, indicating that
depurination of A771 and A1006 abolished binding of
CP to these fragments.
Thermal stability of RNA3 fragment depurinated at A771
We hypothesized that the difference in binding afﬁnity of
CP for depurinated compared with non-depurinated RNA
was due to decrease in stability of the local RNA struc-
ture. To test this possibility, a 162-nt fragment of RNA3
(nt 679–840) containing A771 was treated with PAP or
buffer alone, and its thermal stability measured by UV
spectrophotometry. Depurination of the RNA fragment
at A771 was conﬁrmed by primer extension (data not
shown). The average melting temperature of the
depurinated RNA3 fragment was 57.6 C (long broken
line) compared with the non-depurinated fragment at
62.5 C (solid line; Figure 9). Interestingly, the melting
temperature of the RNA fragment in which A771 was
mutated to T771 was the same as wild-type, at 62.5 C
(short broken line). Therefore, substitution of the purine
for a pyrimidine did not alter the overall thermal stability
of the RNA fragment. The lower melting temperature of
depurinated RNA indicates a higher thermal instability
and ﬂexibility relative to both non-depurinated and
mutated RNA.
RNA3 depurinated at A771 and A1006 is not packaged
in vivo
To determine whether depurination at nucleotides A771
and A1006 was also critical for RNA3 packaging in vivo,
the RNA3 mutants tested for in vitro assembly were trans-
fected, along with wild-type RNA1 and 2, into barley B
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Figure 9. Thermal stability of RNA3 fragment depurinated at A771.
The 162-nt cDNA constructs of RNA3 containing either A771 (wt
cDNA3 fragment) or this nucleotide mutated to T771 (R-cDNA3
fragment) were produced by PCR. In vitro transcripts of these
cDNAs were treated with PAP or buffer alone. The melting tempera-
tures of the RNA fragments were measured by UV spectrophotometry.
The ﬁrst derivative of the absorbance at 260nm was plotted as a
function of temperature. Wild-type RNA3 fragment is represented by
a continuous line, PAP-treated wild-type RNA3 fragment by long
broken lines and R-RNA3 fragment by short broken lines. The absorb-
ance of each fragment was measured independently and values are
means of each ± SE for three separate experiments.
Nucleic Acids Research, 2011,Vol.39, No. 16 7219protoplasts expressing PAP. Assessment by radiolabeled
PCR of the quality of the RNA packaged indicated that
RNA3 depurinated at only A771 or A1006 was excluded
from particles, given that a similar amount of PCR
product was observed from equal amount of virion
RNA3 template from PAP-expressing and wild-type
protoplasts (Figure 10A). In contrast, RNA3 that was re-
sistant to depurination at A771 and A1006 but could be
depurinated elsewhere (RNA3 771 1006-R) was incor-
porated into particles, as seen by the decreased amount
of PCR product, indicative of incomplete reverse tran-
scription due to damaged RNA3 in viral particles from
PAP-expressing protoplasts. To test whether the lack of
incorporation of RNA3 depurinated at A771 or A1006
was due to insufﬁcient depurinated RNA3 in cells, total
RNA3 from protoplasts was extracted and the level of
depurination estimated by reverse transcription.
Radiolabeled cDNA products were extended using a
primer that annealed to the 30-end of RNA3, and
depurination resulted in fragments of expected sizes that
were less than full-length RNA3. The intensities of bands
representing depurination at A771 (for R-RNA3 771),
depurination at A1006 (R-RNA3 1006) and depurination
at A1971 (the most 30 depurinated nucleotide for RNA3
771 1006-R and wt RNA3) were plotted relative to total
RNA3 (Figure 10B). Approximately 70% of each mutant
RNA3 was depurinated, suggesting that lack of
depurinated RNA3 in particles containing R-RNA3 771
or R-RNA3 1006 was not due to lack of depurinated
template inside cells.
DISCUSSION
We observed that PAP expression inhibits the production
of virion particles in barley protoplasts transfected with
BMV RNAs. Fewer virus particles were formed in
PAP-expressing cells; however, their quality and infectiv-
ity were not reduced. A decrease in number was also
observed when particles were assembled in vitro from
isolated CP and PAP-treated RNA3 transcript, suggesting
that PAP decreased the ﬁtness of the RNA for packaging.
Examination of RNA3 from particles revealed that of the
14 possible depurinated nucleotides, only depurination of
A771 in ORF3 and A1006 in the intergenic region pre-
vented incorporation of the RNA. Some speciﬁc inter-
actions between CP and RNA3 appear to regulate
packaging. Initial competition experiments between
BMV RNA, yeast tRNA and Alfalfa mosaic virus RNA
resulted in the preferential packaging of BMV RNAs by
BMV CP (21). It has been shown since that a 187-nt
fragment of the ORF3 of RNA3 is a speciﬁc recognition
element for the CP (12). Deletion of this fragment from
RNA3 resulted in a mutant that was not packaged. We
have identiﬁed a single nucleotide within this region,
A771, which when depurinated, inhibits binding of CP
to RNA3. CP detects damage to this nucleotide and
does not efﬁciently package the depurinated RNA3. We
suggest that A771, along with A1006 of the intergenic
region, are located within RNA elements that impart
speciﬁcity during initial recognition by the CP.
Deletion mutations within RNA3 have shown that
complete removal of the intergenic region did not nega-
tively affect packaging (12). We have observed the same
result (data not shown); however, depurination of A1006
within this region inhibited CP binding and excluded the
RNA from packaging. Even though packaging occurs
in vitro in the absence of the intergenic region, perhaps
when present, this intergenic structure regulates the
speciﬁc interaction of CP with the region of ORF3 con-
taining A771. We have noted previously an unexpected
role for the intergenic region in viral replication; namely,
that replicase binding to the intergenic region is required
for initiation of negative strand synthesis, even though this
region is distant from the 30 terminal core promoter for the
replicase. Depurination of A1006 prevented replicase
binding to RNA3 and initiation of RNA synthesis (14).
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Figure 10. Effect of depurination at A771 and A1006 on the quality of
RNA3 packaged in vivo. In vitro transcripts of RNA1, 2 and either
wild-type or mutant RNA3 were transfected into barley protoplasts
along with a plasmid encoding the PAP gene (+PAP) or empty
plasmid ( PAP) and allowed to replicate for 18h before viral particles
were isolated. (A) RNAs were isolated from viral particles and equal
amounts of gel puriﬁed RNA3 (0.5mg) were used for reverse transcrip-
tion and radioactive PCR. Values are means of intensities for
RNA3±SE for three separate experiments. (B) Total RNA was
isolated from protoplasts, RNA3 was gel puriﬁed and reverse
transcribed in the presence of [a
33P]-dATP. The intensities of truncated
bands, due to depurination, were plotted relative to total RNA3. Bars
represent mean percent depurination±SE for three separate experi-
ments of wtRNA3 and each mutant.
7220 Nucleic Acids Research, 2011,Vol.39, No. 16CP also co-puriﬁes with active replicase complex (22) and
the replicase has been shown to play a role in assembly as
a speciﬁcity ﬁlter, blocking cellular mRNA packaging into
particles (23). Taken together, we speculate that in vivo,
the CP associates with the replicase at the intergenic
region, and that this complex distinguishes viral RNAs.
In vitro, in the absence of replicase, CP can still recognize
damage to the intergenic region and will not bind.
However, if the IGR is removed, CP looses this form of
regulation and binding is achieved by interaction with the
speciﬁc site within ORF3 containing A771. The existence
of two distant regions that bind CP suggests that the
tertiary structure of the viral RNA contributes to
speciﬁcity.
We have shown here that CP can distinguish between
damaged RNA3, in the form of depurination at particular
sites, and intact RNA3. It was of interest to us that this
distinction does not rely on the identity of individual nu-
cleotides because mutation of A771 and A1006 to pyrimi-
dines did not decrease CP binding. Secondary structure
predictions based on M-fold analysis indicated that in
wild-type RNA3, A771 and A1006 are within loop
regions and their mutation to pyrimidines would likely
create stem regions that incorporate these nucleotides.
The potential establishment of base-pairing and the result-
ing change in shape of the RNA were also not sufﬁcient to
affect CP binding. We hypothesize that the fundamental
difference between an intact nucleotide, regardless of
identity, and an abasic nucleotide is stability. Overlap
between pi orbitals of bases in single-stranded RNA
provides substantial stability to the molecule (24,25).
Depurination of a nucleotide will disorder the local struc-
ture and increase its ﬂexibility due to disruption of
base-stacking from the missing purine. We tested this as-
sertion by measuring the melting temperature of a
fragment of RNA3 that was depurinated at A771. The
melting temperature of the depurinated fragment was con-
sistently lower than the intact fragment. The increased
ﬂexibility of a depurinated RNA may mean that recogni-
tion structures are not always accessible for CP binding.
Therefore, we suggest that this instability is detected by
CP, given that its afﬁnity for depurinated nucleotides
within these RNA packaging signals was signiﬁcantly
reduced. Interestingly, no difference in melting tempera-
ture was detected between the intact wild-type fragment
and the same fragment for which the purine was mutated
to a pyrimidine. CP also bound with the same afﬁnity to
full-length resistant RNA3 as wild-type RNA3, support-
ing our view that the stability of particular RNA regions,
rather than their nucleotide sequences, inﬂuences whether
the RNA will be packaged.
Examining the effects of damage to RNA3 through
depurination has provided us with new understanding of
the regulatory role of CP during packaging of virus par-
ticles. Namely, we show that depurination of two nucleo-
tides, one within the ORF3 and the other within the
intergenic region of RNA3, prevents CP binding to the
RNA. Depurination of 12 other nucleotides along the
RNA3 did not inhibit packaging; therefore, the CP recog-
nizes speciﬁc regions of RNA3 that may serve as initial
recognition elements. Not all nucleotides within these
regions are sequence dependent however, as substitution
of the abasic purines to pyrimidines did not diminish CP
interaction with the RNA. Rather, we suggest that the
damage to speciﬁc packaging signals of RNA3 containing
these two nucleotides results in localized instability of the
RNA molecule, which is detected by CP and rejected for
incorporation into particles. Future work will focus on the
role of the replicase, together with CP for packaging
in vivo and will identify whether a structural connection
between A771 of ORF3 and A1006 of the intergenic
region exists to facilitate RNA3 packaging.
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